RxDoctor Payments Data

David Marsh

Nurse Practitioner · Maryville, TNNPI 1588627822

Payments from drug & device makers

$6,312in general payments, 2019–2025

Across 351 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$764
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$731
  • Gilead$720
  • Takeda Pharmaceuticals U.S.A., Inc.$457
  • Bristol Myers Squibb$373
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$6,14397%
  • Education$1693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,312 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,285
Medicare patients
25
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin39$124,135
Humira(Cf) PenAdalimumab12$113,226
LinzessLinaclotide47$30,279
VemlidyTenofovir Alafenamide19$26,723
Ursodiol23$3,324
Mesalamine15$3,036
Famotidine134$2,268
Omeprazole136$2,093
Colestipol Hcl23$1,754
Tenofovir Disoproxil Fumarate23$1,701
Dicyclomine Hcl37$1,071
Esomeprazole Magnesium21$770
Sucralfate14$543
Pantoprazole Sodium115$526
Rabeprazole Sodium21$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$731$124,13539 claims
AbbVieLinzess$1,804$30,27947 claims
GileadVemlidy$720$26,72319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →